Telix Pharmaceuticals (TLX) Price & Analysis

Compare

318 Followers

TLX Stock Chart & Stats

Day’s Range― - ―

52-Week RangeAU$16.02 - AU$31.97

Previous CloseN/A

Volume456.62K

Average Volume (3M)1.47M

Market Cap

$8.82B

Enterprise ValueN/A

Total Cash (Recent Filing)$118.84M

Total Debt (Recent Filing)AU$22.14M

Price to Earnings (P/E)172.8

Beta1.38

Next Earnings

Aug 21, 2025

EPS Estimate

0.35

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.06

Shares Outstanding338,109,040

10 Day Avg. Volume1,029,590

30 Day Avg. Volume1,470,657

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)0.00

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$35.05

Price Target Upside34.29% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

Telix Pharmaceuticals News

PremiumCompany Announcements

Telix Pharmaceuticals Announces Director Change

12d ago

PremiumCompany Announcements

Telix Pharmaceuticals’ AGM Resolutions Successfully Passed

13d ago

PremiumCompany Announcements

Telix Pharmaceuticals Expands Global Reach with Product Approvals

13d ago

PremiumCompany Announcements

Telix Pharmaceuticals Expands Global Product Approvals

13d ago

PremiumCompany Announcements

Telix Pharmaceuticals to Release Shares from Voluntary Escrow

15d ago

PremiumCompany Announcements

Telix Pharmaceuticals Expands Market Presence with New Securities Quotation

18d ago

PremiumCompany Announcements

Telix Pharmaceuticals Issues New Equity Securities

18d ago

PremiumCompany Announcements

Telix Pharmaceuticals Announces Cessation of Share Rights

18d ago

See All AU:TLX News

See All News >

Bulls Say, Bears Say

Bulls Say

Financial PerformanceTelix reported Q1 total revenue of $186MM (AU$296MM, +31% Q/Q, +62% Y/Y), which included $151MM (AU$241MM, +9% Q/Q, +35% Y/Y) of global Illuccix revenue and $33MM (AU$53MM) of RLS revenue since the acquisition closed.

Product ApprovalsApprovals of Zircaix and Pixclara and Illuccix reimbursement decisions ex-US could lead to additional revenue.

Revenue GrowthThe company is on track to exceed H1 revenue consensus of AU$547MM if growth continues at the same pace as Q1 revenue suggests a AU$592 H1 run-rate which is AU$45 above current.

Bears Say

Product DelaysZircaix revenue is delayed to the second half of 2025 due to the NDA resubmission requirement.

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

6.65% Insiders

3.02%

Mutual Funds

― Other Institutional Investors

86.25% Public Companies and

Individual Investors

Detailed Ownership Overview >

TLX FAQ

What was Telix Pharmaceuticals Ltd.’s price range in the past 12 months?

Telix Pharmaceuticals Ltd. lowest share price was AU$16.02 and its highest was AU$31.97 in the past 12 months.

What is Telix Pharmaceuticals Ltd.’s market cap?

Telix Pharmaceuticals Ltd.’s market cap is $8.82B.

When is Telix Pharmaceuticals Ltd.’s upcoming earnings report date?

Telix Pharmaceuticals Ltd.’s upcoming earnings report date is Aug 21, 2025 which is in 79 days.

How were Telix Pharmaceuticals Ltd.’s earnings last quarter?

Telix Pharmaceuticals Ltd. released its earnings results on Feb 20, 2025. The company reported AU$0.06 earnings per share for the quarter, the consensus estimate of AU$0.06 by AU$0.

Is Telix Pharmaceuticals Ltd. overvalued?

According to Wall Street analysts Telix Pharmaceuticals Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Telix Pharmaceuticals Ltd. pay dividends?

Telix Pharmaceuticals Ltd. does not currently pay dividends.

What is Telix Pharmaceuticals Ltd.’s EPS estimate?

Telix Pharmaceuticals Ltd.’s EPS estimate is 0.35.

How many shares outstanding does Telix Pharmaceuticals Ltd. have?

Telix Pharmaceuticals Ltd. has 338,109,040 shares outstanding.

What happened to Telix Pharmaceuticals Ltd.’s price movement after its last earnings report?

Telix Pharmaceuticals Ltd. reported an EPS of AU$0.06 in its last earnings report, expectations of AU$0.06. Following the earnings report the stock price went down -1.342%.

Which hedge fund is a major shareholder of Telix Pharmaceuticals Ltd.?

Currently, no hedge funds are holding shares in AU:TLX

Telix Pharmaceuticals Stock Smart Score

Outperform

Fundamentals

Return on Equity

14.52%

Trailing 12-Months

Asset Growth

244.30%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Telix Pharmaceuticals Ltd.

Telix Pharmaceuticals Ltd. (TLX) is a biotechnology company focused on the development and commercialization of diagnostic and therapeutic products for oncology and rare diseases. The company specializes in molecularly targeted radiation, known as radiopharmaceuticals, which are designed to address significant unmet medical needs in cancer care. Telix's core products include imaging and therapeutic radiopharmaceuticals that aim to enhance the diagnosis and treatment of various cancers, including prostate, kidney, and brain cancers.

TLX Company Deck

TLX Earnings Call

Q4 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects strong financial performance and strategic growth through acquisitions and R&D investments. Despite potential regulatory delays and market uncertainties, Telix is well-positioned for significant expansion with an innovative product pipeline.Read More>

TLX Stock 12 Month Forecast

Average Price Target

AU$35.05

▲(34.29%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"AU$13","19":"AU$19","25":"AU$25","31":"AU$31","37":"AU$37"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":36.1494634626864,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$36.15</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35.0489814248,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$35.05</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34.1411599369816,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$34.14</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,19,25,31,37],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.99,28.61765103559126,29.245302071182522,29.87295310677378,30.500604142365045,31.128255177956305,31.75590621354757,32.38355724913883,33.01120828473009,33.63885932032135,34.266510355912615,34.89416139150388,35.521812427095135,{"y":36.1494634626864,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.99,28.53299857113846,29.075997142276922,29.618995713415384,30.161994284553845,30.704992855692307,31.24799142683077,31.790989997969227,32.33398856910769,32.87698714024615,33.41998571138461,33.962984282523074,34.505982853661536,{"y":35.0489814248,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.99,28.46316614899858,28.93633229799717,29.40949844699575,29.88266459599434,30.35583074499292,30.82899689399151,31.30216304299009,31.77532919198868,32.24849534098726,32.72166148998585,33.194827638984435,33.667993787983015,{"y":34.1411599369816,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.67,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.15,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.09,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.35,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.01,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.97,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.45,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.55,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.61,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.34,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.46,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.35,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.99,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >